Healthspan Economy

Pillar P4

Healthtech & Diagnostics

Healthtech and diagnostics: the measurement layer of the healthspan economy, from advanced imaging to consumer diagnostics.

55 entities

AMILI

Precision gut microbiome diagnostics and FMT bank; largest multi-ethnic Asian microbiome database

AMILI is Southeast Asia's leading precision gut microbiome company, founded in Singapore in 2019, and runs the region's only microbiome transplant bank. It offers clinical gut health testing, microbiome restoration therapy, AI-powered analytics for healthcare partners, and physician-guided probiotic programs, and holds the world's largest multi-ethnic Asian gut microbiome database. Backed by Vulcan Capital and East Ventures, it collaborates with NUS, NUH, and Monash University.

Lab Singapore Available on request
P4

Insighta

USD 200M JV between Prenetics and CUHK's Prof. Dennis Lo for multi-cancer early detection; largest private life sciences deal in Hong Kong history

Insighta is a USD 200 million joint venture established in 2023 between Prenetics Global and Prof. Dennis Lo of CUHK, headquartered at Hong Kong Science and Technology Park. It is commercializing Presight, a multi-cancer early detection blood test initially focused on liver and lung cancer, with commercial launch in Hong Kong and mainland China targeted for 2025, and a multi-cancer (10-plus) version planned for 2027. This is described as the largest private life sciences deal in Hong Kong history.

Lab Hong Kong SAR Available on request
P4

Kakao Healthcare

AI health data platform, diabetes management, preventive digital health

Kakao Healthcare (est. 2021, CEO Hwang Hee) is a Kakao Corp digital health subsidiary building a unified personal health data ecosystem. Its PASTA CGM diabetes management platform launched 2023. KRW 176B (approx. USD 133M) raised from SK Telecom and Korea National Pension Service. Developing a health data super-app connecting hospital records, wearables, and AI health coaching.

Platform South Korea consumer app pricing varies; PASTA subscription model
P4

Lifeyear

Digital cardiometabolic care (B2B NHS)

Specialist-led remote cardiometabolic care platform for NHS Trusts and European hospitals. Covers heart failure, cardiac rehab, lipids, hypertension, and diabetes pathways. Clinician dashboard, patient app, and connected medical-grade devices. Clinical partners: Oxford University Hospitals NHS Foundation Trust (shareholder), Oxford Health, Tartu University Hospital, North Estonia Medical Centre. NHS DSPT and DTAC compliant; Cyber Essentials certified.

Platform United Kingdom
P4 Virtual

MedGenome Labs

Clinical genomics diagnostics

MedGenome Labs is the market leader for genetic diagnostic testing in India and South Asia, operating a CAP- and NABL-accredited next-generation sequencing reference laboratory in Electronic City, Bengaluru. The lab offers more than 1,300 genetic tests spanning oncology, rare diseases, reproductive genetics, neurology, and preventive wellness screening. Founded in 2013, the company has raised USD 264 million across ten funding rounds, with the most recent Series E closing at USD 47.5 million in July 2025.

Lab India Available on request
P4

Mirxes

RNA-based multi-cancer early detection diagnostics; Southeast Asia's first biotech unicorn (HKEX IPO May 2025)

Mirxes is a Singapore-founded biotech diagnostics company specializing in miRNA-based liquid biopsy and early cancer detection, achieving Southeast Asia's first biotech unicorn status upon its HKEX IPO in May 2025. Its flagship products include GASTROClear (the world's first blood test for gastric cancer early detection, FDA Breakthrough Device designated) and LUNGClear for lung cancer. The company operates clinical sequencing, precision multiomics, and biobanking services through a public-private partnership center for specialty molecular testing in Singapore.

Lab Singapore Available on request; B2B clinical test pricing through hospital and clinic partners
P4

Novo Genomics

Saudi Arabia's first CAP-accredited genomics and precision medicine laboratory

Novo Genomics is Saudi Arabia's first CAP-accredited genomics laboratory, headquartered in Riyadh and focused on localizing next-generation sequencing, multi-omics, and pharmacogenomics to support Vision 2030 precision medicine goals. The lab offers whole genome and whole exome sequencing, targeted gene panels, molecular diagnostics, genetic counseling, and non-invasive prenatal testing. It partnered with PGxAI to deploy AI-enabled pharmacogenomics across the Kingdom; CAP re-accreditation confirmed in 2025.

Lab Saudi Arabia Available on request
P4

Prenetics / CircleDNA

NASDAQ-listed (PRE) genomic diagnostics and preventive health platform; CircleDNA available at 240-plus Watsons HK locations

Prenetics is a Hong Kong-based, NASDAQ-listed health sciences company co-founded in 2014 by Danny Yeung that operates CircleDNA, the world's most comprehensive consumer DNA test using whole exome sequencing to deliver 500-plus health, ancestry, and pharmacogenomics reports. Its subsidiary Insighta, a USD 200 million joint venture with Prof. Dennis Lo of CUHK, is commercializing Presight, a multi-cancer early detection blood test targeting initial launch in Hong Kong and mainland China in 2025. CircleDNA is available at over 240 Watsons locations across Hong Kong.

Platform Hong Kong SAR Available on request
P4

FAQ

Frequently asked questions

What does the Healthtech & Diagnostics pillar cover?

Healthtech and diagnostics is the measurement layer of the healthspan economy: advanced imaging, at-home and consumer diagnostics, biological age testing, and the platforms that interpret the data. This pillar of the Healthspan Economy Atlas currently maps 55 entities across 20 markets.

How are companies in this pillar selected?

Inclusion in the Atlas is editorial, not paid. We map the premium end of the pillar: operators with a defined clinical or product offering, real market presence, and relevance to how the healthspan economy is forming. No company can pay for inclusion or placement.

Is this data free to cite?

Yes. The Atlas is free to read and cite with attribution to Healthspan Economy and a link to healthspaneconomy.com.